ovarian cancer
Oncology · 2013–2025
18decisions
5medicines
15carried consumer input
100individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| mirvetuximab soravtansine Treatment of patients with platinum-resistant high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received at least one prior… | Nov 2025 | Recommended | 1 individuals |
| bevacizumab Metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small cell lung cancer, advanced… | Mar 2024 | Recommended with restriction | 1 individuals |
| niraparib Maintenance therapy in patients with newly diagnosed advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that is HRD positive… | Jul 2023 | Recommended | input received |
| olaparib Maintenance therapy in patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (FIGO stage III-IV) that is HRD… | Jul 2023 | Recommended | input received Ovarian Cancer Australia |
| olaparib Maintenance treatment of adult patients with newly diagnosed advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or… | Jul 2022 | Not recommended | input received Ovarian Cancer Australia |
| niraparib Maintenance therapy for newly diagnosed advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in patients in response to… | Mar 2022 | Recommended with restriction | 55 individuals Ovarian Cancer Australia · Medical Oncology Group |
| niraparib First-line maintenance treatment of adult patients with newly diagnosed advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer… | Jul 2021 | Not recommended | input received Ovarian Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| niraparib Maintenance treatment of platinum-sensitive relapsed high grade serous ovarian, fallopian tube, or primary peritoneal cancer in patients in response (complete… | Mar 2021 | Not recommended | 14 individuals Ovarian Cancer Research Foundation · Ovarian Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| olaparib Maintenance treatment of patients with newly diagnosed advanced (FIGO stage III-IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer… | Jul 2020 | Recommended | input received Ovarian Cancer Australia · Rare Cancers Australia · Medical Oncology Group |
| topotecan Treatment of metastatic carcinoma of the ovary after failure of first-line or subsequent therapy; small cell lung carcinoma after failure of first-line… | Jul 2020 | Recommended with restriction | input received Lung Foundation Australia |
| olaparib Maintenance treatment of platinum-sensitive relapsed ovarian, fallopian tube and primary peritoneal cancer in patients with somatic BRCA1/2 mutations (in… | Mar 2020 | Recommended | 1 individuals |
| olaparib Maintenance treatment of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer (FIGO stage III-IV) with… | Nov 2019 | Not recommended | input received Ovarian Cancer Australia |
| olaparib Maintenance treatment of women with germline BRCA1 or BRCA2 gene mutation and platinum-sensitive relapsed high-grade serous ovarian, fallopian tube, or primary… | Mar 2018 | Recommended with restriction | unclear |
| olaparib Maintenance treatment of women with BRCAm platinum-sensitive relapsed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are in response… | Jul 2016 | Not recommended | input received |
| olaparib Maintenance treatment of women with BRCA1 or BRCA2 gene mutation and platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer who are… | Mar 2016 | Deferred | 28 individuals |
| olaparib Maintenance treatment of women with BRCAm platinum-sensitive relapsed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who are in response… | Nov 2016 | Recommended with restriction | unclear |
| bevacizumab First-line treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO Stage IIIB, IIIC or Stage IV) in combination with… | Mar 2014 | Not recommended | input received Medical Oncology Group |
| bevacizumab First-line treatment of previously untreated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer (FIGO Stages IIIB, IIIC or IV) with… | Nov 2013 | Recommended with restriction | no section in document |
Who spoke
Ovarian Cancer Australia · Medical Oncology Group · Rare Cancers Australia · Ovarian Cancer Research Foundation · Lung Foundation Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 15 of 17 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.